Articles

NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.

January/February's product news

The pros and cons of surface ablation procedures were reviewed at the opening session of the refractive surgery subspecialty day at the American Academy of Ophthalmology annual meeting.

January/February research news

I recently attended a party where I was drawn into a conversation by some people who had one thing in common – LASIK. Somebody amongst the group had undergone the procedure six years ago (incidentally, that was my sister) whilst another underwent wavefront-guided LASIK just weeks prior. Each of the four people had a story to tell about their experience with the procedure but, overall, each claimed they were happy with the end result.

A controversial decision by NICE to limit the use of the anti-VEGF drug Lucentis in treating patients with wet AMD, is being reconsidered.

Tempted?

The World Economic Forum has selected 39 companies as Technology Pioneers for 2008 and NuLens is one of those honoured with this title.

With additional training, optometrists are at least as accurate as junior ophthalmologists in diagnosing glaucoma.

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

OPKO Health has completed its acquisition of Ophthalmic Technologies Inc. (OTI), a privately owned Canadian company.

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

Barry G. Caldwell has been named as the new President and Chief Executive Officer of STAAR Surgical.

The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.

Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.

Have a look at the AMD therapies taking the first step along the path to approval.

What therapies have made it to Phase II clinical trials?

Take a look at the therapies that have reached Phase III clinical testing.

Take a look at the therapies that have already reached the market.

What are doctors using off-label to treat their AMD patients?

Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA.

Intravitreal bevacizumab (Avastin) performs better than verteporfin photodynamic therapy (PDT) in the management of choroidal neovascularization (CNV) in age-related macular degeneration.

Ophtherion has licensed the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10, from the University of Pittsburgh, USA.

Triple therapy consisting of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation may facilitate early recovery of vision in patients with intractable diabetic macular oedema.

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

Using a decagonal transplant shape in perforating keratoplasties (pKPL) delivers promising results.

A study of patients with ankylosing spondylitis (AS) treated with Humira, a tumour necrosis factor alpha (TNF-alpha) blocker, has found that the drug cuts the rate of uveitis flares by approximately half.

Patients undergoing 25-gauge vitreoretinal surgery are more likely to experience postoperative serous choroidal effusion and hypotony than patients undergoing 20-gauge procedures.

STAAR Surgical has entered into an agreement to acquire the interests of all other shareholders in Canon Staar.

Genentech is delaying its plan to restrict the use of Avastin by ophthalmologists in the US until January 2008.